These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26935981)

  • 61. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome.
    Ammouri W; Cuisset L; Rouaghe S; Rolland MO; Delpech M; Grateau G; Ravet N
    Rheumatology (Oxford); 2007 Oct; 46(10):1597-600. PubMed ID: 17804452
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mevalonate kinase deficiency: current perspectives.
    Favier LA; Schulert GS
    Appl Clin Genet; 2016; 9():101-10. PubMed ID: 27499643
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome.
    Hager EJ; Tse HM; Piganelli JD; Gupta M; Baetscher M; Tse TE; Pappu AS; Steiner RD; Hoffmann GF; Gibson KM
    J Inherit Metab Dis; 2007 Nov; 30(6):888-95. PubMed ID: 18008182
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.
    Tricarico PM; Kleiner G; Valencic E; Campisciano G; Girardelli M; Crovella S; Knowles A; Marcuzzi A
    Int J Mol Sci; 2014 Apr; 15(4):6843-56. PubMed ID: 24758928
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology.
    Marcuzzi A; Piscianz E; Zweyer M; Bortul R; Loganes C; Girardelli M; Baj G; Monasta L; Celeghini C
    Int J Mol Sci; 2016 Mar; 17(3):365. PubMed ID: 26978350
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hyper-IgD and periodic fever syndrome: a new MVK mutation (p.R277G) associated with a severe phenotype.
    Santos JA; Aróstegui JI; Brito MJ; Neves C; Conde M
    Gene; 2014 Jun; 542(2):217-20. PubMed ID: 24656624
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mevalonate kinase deficiency presenting as recurrent rectal abscesses and perianal fistulae.
    Dunn K; Pasternak B; Kelsen JR; Sullivan KE; Dawany N; Wright BL
    Ann Allergy Asthma Immunol; 2018 Feb; 120(2):214-215. PubMed ID: 29290516
    [No Abstract]   [Full Text] [Related]  

  • 68. Natural history of mevalonate kinase deficiency: a literature review.
    Zhang S
    Pediatr Rheumatol Online J; 2016 May; 14(1):30. PubMed ID: 27142780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Different presentations of mevalonate kinase deficiency: a case series.
    De Pieri C; Taddio A; Insalaco A; Barbi E; Lepore L; Ventura A; Tommasini A
    Clin Exp Rheumatol; 2015; 33(3):437-42. PubMed ID: 25897835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tocilizumab for the Treatment of Mevalonate Kinase Deficiency.
    Rafiq NK; Lachmann H; Joensen F; Herlin T; Brogan PA
    Case Rep Pediatr; 2018; 2018():3514645. PubMed ID: 30225156
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Knockdown of MVK does not lead to changes in NALP3 expression or activation.
    Celsi F; Piscianz E; Romano M; Crovella S
    J Inflamm (Lond); 2015; 12():7. PubMed ID: 25663823
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Autoinflammatory gene mutations in Behçet's disease.
    Koné-Paut I; Sanchez E; Le Quellec A; Manna R; Touitou I
    Ann Rheum Dis; 2007 Jun; 66(6):832-4. PubMed ID: 17213252
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome.
    Cuisset L; Drenth JP; Simon A; Vincent MF; van der Velde Visser S; van der Meer JW; Grateau G; Delpech M;
    Eur J Hum Genet; 2001 Apr; 9(4):260-6. PubMed ID: 11313769
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genomic variations of the mevalonate pathway in porokeratosis.
    Zhang Z; Li C; Wu F; Ma R; Luan J; Yang F; Liu W; Wang L; Zhang S; Liu Y; Gu J; Hua W; Fan M; Peng H; Meng X; Song N; Bi X; Gu C; Zhang Z; Huang Q; Chen L; Xiang L; Xu J; Zheng Z; Jiang Z
    Elife; 2015 Jul; 4():e06322. PubMed ID: 26202976
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.
    Tricarico PM; Marcuzzi A; Piscianz E; Monasta L; Crovella S; Kleiner G
    Int J Mol Sci; 2013 Nov; 14(12):23274-88. PubMed ID: 24287904
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Autoinflammatory diseases.
    Touitou I; Koné-Paut I
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):811-29. PubMed ID: 19028365
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An Atypical Presentation of Mevalonate Kinase Deficiency in Response to Colchicine Treatment.
    Koç Yekedüz M; Doğulu N; Öncül Ü; Köse E; Ceylaner S; Eminoğlu FT
    Mol Syndromol; 2022 Feb; 13(2):146-151. PubMed ID: 35418827
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study.
    Kleiner G; Celsi F; Tricarico PM; Zacchigna S; Crovella S; Marcuzzi A
    In Vivo; 2013; 27(6):715-22. PubMed ID: 24292573
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS).
    Messer L; Alsaleh G; Georgel P; Carapito R; Waterham HR; Dali-Youcef N; Bahram S; Sibilia J
    RMD Open; 2016; 2(1):e000196. PubMed ID: 26977311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.